Meeting
2020 ASCO Virtual Scientific Program
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
Authors
Robert Wesolowski
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Robert Wesolowski , Nuzhat Pathan , Zhou Zhu , Erica Michelle Stringer-Reasor , Hyo S. Han , Elizabeth Claire Dees , Aditya Bardia , Rachel M. Layman , Amy Weise , Peter Kabos , Janice M. Lu , Kenneth Alan Kern , Kristen J. Pierce , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02684032
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1052)
DOI
10.1200/JCO.2020.38.15_suppl.1052
Abstract #
1052
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).
First Author: Andres Forero-Torres
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2018 ASCO Annual Meeting
Mutation signature of patients with ER+ metastatic breast cancer who received endocrine therapy.
First Author: Fei Ma